Abstract
There is an urgent need to improve the pharmacotherapy of schizophrenia despite the introduction of important new medications. New treatment insights may come from appreciating the therapeutic implications of model psychoses. In particular, basic and clinical studies have employed the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, as a probe of NMDA receptor contributions to cognition and behavior. These studies illustrate a translational neuroscience approach for probing mechanistic hypotheses related to the neurobiology and treatment of schizophrenia and other disorders. Two particular pathophysiologic themes associated with schizophrenia, the disturbance of cortical connectivity and the disinhibition of glutamatergic activity may be modeled by the administration of NMDA receptor antagonists. The purpose of this review is to consider the possibility that agents that attenuate these two components of NMDA receptor antagonist response may play complementary roles in the treatment of schizophrenia.
Similar content being viewed by others
References
Abel KM, Allin MP, Kucharska-Pietura K, Andrew C, Williams S, David AS, Phillips ML (2003) Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in blood flow versus change in cognitive state. Hum Brain Mapp 18:135–145
Abi-Dargham A, Laruelle M, Krystal J, D'Souza C, Zoghbi S, Baldwin RM, Seibyl J, Mawlawi O, de Erasquin G, Charney D, Innis RB (1999) No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology 20:650–661
Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M (2000) From the cover: increased baseline occupancy of D2 receptors by dopamine in schizophrenia Proc Natl Acad Sci USA 97:8104–8109
Abi-Saab W, D'Souza DC, Moghaddam B, Krystal JH (1998) The NMDA antagonist model for schizophrenia: promises and pitfalls. Pharmacopsychiatry 31:104–109
Adler CM, Malhotra AK, Goldberg T, Elman I, Pickar D, Breier A (1998) A comparison of ketamine-induced and schizophrenic thought disorder. In: 53rd annual convention, Society of Biological Psychiatry, Toronto, Canada, pp 83S–84S
Afanas'ev I, Kudrin V, Rayevsky KS, Varga V, Saransaari P, Oja SS (1999) Lamotrigine and carbamazepine affect differently the release of D-[3H]aspartate from mouse cerebral cortex slices: involvement of NO. Neurochem Res 24:1153–1159
Aghajanian GK, Marek GJ (1999) Serotonin-glutamate interactions: a new target for antipsychotic drugs. Neuropsychopharmacology 21:S122–S133
Akbarian S, Bunney WE Jr, Potkin SG, Wigal SB, Hagman JO, Sandman CA, Jones EG (1993a) Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 50:169–177
Akbarian S, Vinuela A, Kim JJ, Potkin SG, Bunney WE Jr, Jones EG (1993b) Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 50:178–187
Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr, Jones EG (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52:258–266
Akbarian S, Kim JJ, Potkin SG, Hetrick WP, Bunney WE Jr, Jones EG (1996) Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry 53:425–436
Alonso R, Gnanadicom H, Frechin N, Fournier M, Le Fur G, Soubrie P (1999) Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain. Eur J Neurosci 11:967–974
Anand A, Charney DS, Cappiello A, Berman RM, Oren DA, Krystal JH (2000) Lamotrigine attenuates ketamine effects in humans: support for hyperglutamatergic effects of NMDA antagonists. Arch Gen Psychiatry 57:270–276
Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL, Hichwa RD (1997) Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 349:1730–1734
Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79:565–575
Arnold SE, Franz BR, Gur RC, Gur RE, Shapiro RM, Moberg PJ, Trojanowski JQ (1995) Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am J Psychiatry 152:738–748
Arvanitis LA, Miller BG (1997) Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42:233–246
Avila MT, Weiler MA, Lahti AC, Tamminga CA, Thaker GK (2002) Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am J Psychiatry 159:1490–1496
Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871–7879
Axelsson R, Nilsson A, Christensson E, Bjork A (1991) Effects of amperozide in schizophrenia: an open study of a potent 5-HT2 receptor antagonist. Psychopharmacology 104:287–292
Baldessarini RJ, Kando JC, Centorrino F (1995) Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am J Psychiatry 152:1038–1044
Banerjee SP, Zuck LG, Yablonsky-Alter E, Lidsky TI (1995) Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. NeuroReport 6:2500–2504
Barbeau A (1967) The "pink spot", 3,4-dimethoxyphenylethylamine and dopamine: relationship to Parkinson's disease and to schizophrenia. Rev Can Biol 26:55–79
Barch DM, Carter CS, Braver TS, Sabb FW, MacDonald A 3rd, Noll DC, Cohen JD (2001) Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry 58:280–288
Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, Canaran G, Rylett RJ, Neufeld RW (1997) Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 54:959–965
Bartko G, Horvath S, Zador G, Frecska E (1991) Effects of adjunctive verapamil administration in chronic schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 15:343–349
Beasley CL, Reynolds GP (1997) Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 24:349–355
Belger A, Gatenby C, Kirino E, Madonick S, Gore J, Krystal JH (2003a) Subanesthetic ketamine preferentially disrupts the frontal cortical activation associated with the processing of novelty: an fMRI study in healthy humans. (in review)
Belger A, Kirino E, Vita L, McCarthy G, D'Souza DC, Gore J, Krystal JH (2003b) FMRI and ERP evidence of inferior prefrontal cortex mediation of novelty bias and distractibility in schizophrenia. Arch Gen Psychiatry (in press)
Bell MD, Bryson G (2001) Work rehabilitation in schizophrenia: does cognitive impairment limit improvement? Schizophr Bull 27:269–279
Bell M, Bryson G, Greig T, Corcoran C, Wexler BE (2001) Neurocognitive enhancement therapy with work therapy: effects on neuropsychological test performance. Arch Gen Psychiatry 58:763–768
Benes FM, Berretta S (2001) GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25:1–27
Benes FM, Majocha R, Bird ED, Marotta CA (1987) Increased vertical axon numbers in cingulate cortex of schizophrenics. Arch Gen Psychiatry 44:1017–1021
Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL (1991) Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48:996–1001
Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP (1992) Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 12:924–929
Benes FM, Vincent SL, Marie A, Khan Y (1996) Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75:1021–1031
Bergeron R, Meyer TM, Coyle JT, Greene RW (1998) Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 95:15730–15734
Bertolino A (1999) Increase in frontal cortex Gl-X in healthy human subjects administered ketamine.
Bertolino A, Weinberger DR (1999) Proton magnetic resonance spectroscopy in schizophrenia. Eur J Radiol 30:132–141
Biver F, Delvenne V, Goldman S, Luxen A, De Maertelaer V, Lotstra F, Mendlewicz J (1992) [No hypofrontality in schizophrenia demonstrated by positron emission tomography]. Acta Psychiatr Belg 92:261–278
Bogerts B (1999) The neuropathology of schizophrenic diseases: historical aspects and present knowledge. Eur Arch Psychiatry Clin Neurosci 249:2–13
Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88:82–88
Bowers MB Jr, Freedman DX (1966) "Psychedelic" experiences in acute psychoses. Arch Gen Psychiatry 15:240–248
Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997a) Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154:805–811
Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997b) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569–2574
Brekke JS, Kohrt B, Green MF (2001) Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophr Bull 27:697–708
Brody SA, Geyer MA, Large CH (2003) Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology DOI 10.1007/s00213-003-1421-2
Bryson G, Bell MD, Kaplan E, Greig T (1998) The functional consequences of memory impairments on initial work performance in people with schizophrenia. J Nerv Ment Dis 186:610–615
Buchanan RW, Holstein C, Breier A (1994) The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 36:717–725
Buchsbaum MS, Tang CY, Peled S, Gudbjartsson H, Lu D, Hazlett EA, Downhill J, Haznedar M, Fallon JH, Atlas SW (1998) MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia. Neuroreport 9:425–430
Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381–389
Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV, Kerwin RW (1997) Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia [published erratum appears in Am J Psychiatry (May 1997) 154(5):722] [see comments]. Am J Psychiatry 154:56–63
Carpenter WT Jr (1995) Serotonin-dopamine antagonists and treatment of negative symptoms. J Clin Psychopharmacol 15:30S–35S
Carpenter WT Jr (1996) The treatment of negative symptoms: pharmacological and methodological issues. Br J Psychiatry Suppl:17–22
Carpenter WT Jr (1999) The schizophrenia ketamine challenge study debate. Biol Psychiatry 46:1081–1091
Carpenter WT Jr, Fink EB, Narasimhachari N, Himwich HE (1975) A test of the transmethylation hypothesis in acute schizophrenic patients. Am J Psychiatry 132:1067–1071
Carpenter WT Jr, Kurz R, Kirkpatrick B, Hanlon TE, Summerfelt AT, Buchanan RW, Waltrip RW, Breier A (1991) Carbamazepine maintenance treatment in outpatient schizophrenics. Arch Gen Psychiatry 48:69–72
Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW (2003) Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28:182–192
Catafau AM, Parellada E, Lomena FJ, Bernardo M, Pavia J, Ros D, Setoain J, Gonzalez-Monclus E (1994) Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease. J Nucl Med 35:935–941
Cecil KM, Lenkinski RE, Gur RE, Gur RC (1999) Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology 20:131–140
Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, Bougueleret L, Barry C, Tanaka H, La Rosa P et al. (2002) Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 99:13675–13680
Citrome L, Levine J, Allingham B (1998) Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatr Q 69:283–300
Cleghorn JM, Garnett ES, Nahmias C, Firnau G, Brown GM, Kaplan R, Szechtman H, Szechtman B (1989) Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Res 28:119–133
Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205–237
Cotter D, Landau S, Beasley C, Stevenson R, Chana G, MacMillan L, Everall I (2002) The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry 51:377–386
Coyle JT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3:241–253
Coyle JT (1997) The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis 4:231–238
D'Souza DC, Charney DS, Krystal JH (1995) Glycine site agonists of the NMDA receptor: a review. CNS Drug Rev 1:227–260
D'Souza DC, Gil R, Belger A, Zimmerman L, Tracy L, Larvey K, Cassello K, Krystal J (1997) Glycine-ketamine interactions in healthy humans. In: 36th annual meeting, American College of Neuropsychopharmacology, Kona, HI, p 286
D'Souza DC, Berman RM, Krystal JH, Charney DS (1999) Symptom provocation studies in psychiatric disorders: scientific value, risks and future. Biol Psychiatry (in press)
D'Souza DC, Gil R, MacDougall L, Cassello K, Boutros N, Innis RB, Krystal JH (2003) GABA-serotonin interactions in healthy subjects: implications for psychosis and dissociation. Neuropsychopharmacology (in press)
Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:491–505
Davidson M, Harvey PD, Powchik P, Parrella M, White L, Knobler HY, Losonczy MF, Keefe RS, Katz S, Frecska E (1995) Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry 152:197–207
Daviss SR, Lewis DA (1995) Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons. Psychiatry Res 59:81–96
Deakin JF, Simpson MD (1997) A two-process theory of schizophrenia: evidence from studies in post-mortem brain. J Psychiatr Res 31:277–295
Dean B, Hussain T, Hayes W, Scarr E, Kitsoulis S, Hill C, Opeskin K, Copolov DL (1999) Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J Neurochemistry 72:1593–1599
Diana M, Melis M, Gessa GL (1998) Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 10:2825–2830
Dierks T, Linden DE, Jandl M, Formisano E, Goebel R, Lanfermann H, Singer W (1999) Activation of Heschl's gyrus during auditory hallucinations. Neuron 22:615–621
Domino EF, Chodoff P, Corssen G (1965) Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharm Ther 6:279–291
Dose M, Apelt S, Emrich HM (1987) Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res 22:303–310
Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM (1998) Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 31:122–125
Dunah AW, Standaert DG (2001) Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci 21:5546–5558
Duncan E, Adler L, Angrist B, Rotrosen J (1990) Nifedipine in the treatment of tardive dyskinesia. J Clin Psychopharmacol 10:414–416
Durson SM, McIntosh D, Milliken H (1999) Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry 56:950
Dursun SM, Deakin JF (2001) Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 15:297–301
Eastwood SL, Burnet PW, Harrison PJ (1995) Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 66:309–319
Egan CT, Herrick-Davis K, Teitler M (1998) Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther 286:85–90
Emonds-Alt X, Bichon D, Ducoux JP, Heaulme M, Miloux B, Poncelet M, Proietto V, Van Broeck D, Vilain P, Neliat G et al. (1995) SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci 56:L27–L32
Essock SM, Hargreaves WA, Covell NH, Goethe J (1996) Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 32:683–697
Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC (2000) Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157:826–828
Farber NB, Newcomer JW, Olney JW (1998) The glutamate synapse in neuropsychiatric disorders: focus on schizophrenia and Alzheimer's disease. Prog Brain Res 116:421–437
Farber NB, Newcomer JW, Olney JW (1999) Lamotrigine prevents NMDA antagonist neurotoxicity. Schizophr Res 36:308
Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C (2002) Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 7:32–43
Fauman B, Aldinger G, Fauman M, Rosen P (1976) Psychiatric sequelae of phencyclidine abuse. Clin Toxicol 9:529–538
Fenton WS, McGlashan TH (1991a) Natural history of schizophrenia subtypes. I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. Arch Gen Psychiatry 48:969–977
Fenton WS, McGlashan TH (1991b) Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 48:978–986
Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S (1998) The anatomy of conscious vision: an fMRI study of visual hallucinations. Nature Neurosci 1:738–742
Fletcher PC, McKenna PJ, Frith CD, Grasby PM, Friston KJ, Dolan RJ (1998) Brain activations in schizophrenia during a graded memory task studied with functional neuroimaging. Arch Gen Psychiatry 55:1001–1008
Foong J, Maier M, Barker GJ, Brocklehurst S, Miller DH, Ron MA (2000) In vivo investigation of white matter pathology in schizophrenia with magnetisation transfer imaging. J Neurol Neurosurg Psychiatry 68:70–74
Ford JM, Mathalon DH, Heinks T, Kalba S, Faustman WO, Roth WT (2001a) Neurophysiological evidence of corollary discharge dysfunction in schizophrenia. Am J Psychiatry 158:2069–2071
Ford JM, Mathalon DH, Kalba S, Whitfield S, Faustman WO, Roth WT (2001b) Cortical responsiveness during inner speech in schizophrenia: an event-related potential study. Am J Psychiatry 158:1914–1916
Ford JM, Mathalon DH, Whitfield S, Faustman WO, Roth WT (2002) Reduced communication between frontal and temporal lobes during talking in schizophrenia. Biol Psychiatry 51:485–492
Glantz LA, Lewis DA (1997) Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: regional and diagnostic specificity [corrected and republished article which originally appeared in Arch Gen Psychiatry (1997) 54:660–669]. Arch Gen Psychiatry 54:943–952
Glantz LA, Lewis DA (2000) Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57:65–73
Glantz LA, Lewis DA (2001) Dendritic spine density in schizophrenia and depression. Arch Gen Psychiatry 58:203
Gloor P (1990) Experiential phenomena of temporal lobe epilepsy: facts and hypotheses. Brain 113:1673–1694
Goff DC, Tsai G, Manoach DS, Coyle JT (1995) Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213–1215
Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996) D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153:1628–1630
Goff D, Berman I, Posever T, Leahy L, Lynch G (1999a) A preliminary dose-escalation trial of CX-516 (ampakine) added to clozapine in schizophrenia. Schizophr Res 36:280
Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT (1999b) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia [see comments]. Arch Gen Psychiatry 56:21–27
Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G (2001) A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 21: 484–487
Gold JM, Goldberg RW, McNary SW, Dixon LB, Lehman AF (2002) Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry 159:1395–1402
Goldberg RW, Lucksted A, McNary S, Gold JM, Dixon L, Lehman A (2001) Correlates of long-term unemployment among inner-city adults with serious and persistent mental illness. Psychiatr Serv 52:101–103
Gouzoulis-Mayfrank E, Habermeyer E, Hermle L, Steinmeyer AM, Kunert HJ, Sass H (1998) Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study. Eur Psychiatry 13:399–406
Grebb JA, Shelton RC, Taylor EH, Bigelow LB (1986) A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia. Biol Psychiatry 21:691–694
Green MF, Braff DL (2001) Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry 49:374–384
Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154:799–804
Green SM, Rothrock SG, Lynch EL, Ho M, Harris T, Hestdalen R, Hopkins GA, Garrett W, Westcott K (1998) Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases. Ann Emerg Med 31:688–697
Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Muller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T (1997) Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study. Eur Arch Psychiatry Clin Neurosci 247:42–50
Grimwood S, Wilde GJ, Foster AC (1993) Interactions between the glutamate and glycine recognition sites of the N-methyl-D-aspartate receptor from rat brain, as revealed from radioligand binding studies. J Neurochem 60:1729–1738
Gross CP, Anderson GF, Powe NR (1999) The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 340:1881–1887
Grossberg S (1984) Some normal and abnormal behavioral syndromes due to transmitter gating of opponent processes. Biol Psychiatry 19:1075–1118
Grossberg S (1999) Neural models of normal and abnormal behavior: what do schizophrenia, Parkinsonism, attention deficit disorder, and depression have in common? In: Ruppin E, Reggia JA, Glanzman D (eds) Progress in Brain Research. Elsevier Science, New York, pp 381–414
Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW, Greene RW (1996) NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 16:2034–2043
Grunze H, Greene RW, Moller HJ, Meyer T, Walden J (1998) Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current. Brain Res 791:330–334
Gully D, Jeanjean F, Poncelet M, Steinberg R, Soubrie P, Le Fur G, Maffrand JP (1995) Neuropharmacological profile of non-peptide neurotensin antagonists. Fund Clin Pharmacol 9:513–521
Gur RE, Resnick SM, Alavi A, Gur RC, Caroff S, Dann R, Silver FL, Saykin AJ, Chawluk JB, Kushner M et al. (1987) Regional brain function in schizophrenia. I. A positron emission tomography study. Arch Gen Psychiatry 44:119–125
Gur RE, Mozley PD, Resnick SM, Mozley LH, Shtasel DL, Gallacher F, Arnold SE, Karp JS, Alavi A, Reivich M et al. (1995) Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry 52:657–667
Haas DA, Harper DG (1992) Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog 39:61–68
Haig AR, Gordon E, De Pascalis V, Meares RA, Bahramali H, Harris A (2000) Gamma activity in schizophrenia: evidence of impaired network binding? Clin Neurophysiol 111:1461–1468
Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA (2001) Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98:4746–4751
Halgren E, Walter RD, Cherlow DG, Crandall PH (1978) Mental phenomena evoked by electrical stimulation of the human hippocampal formation and amygdala. Brain 101:83–117
Hanada S, Nishino N, Mita T, Kuno T, Kuyama T, Isoda K, Hosomi T, Uchida S, Kasai T, Nakai H et al. (1984) Increased 3H-muscimol binding in post-mortem brains of chronic schizophrenics. Seishin Shinkeigaku Zasshi 86:225–229
Hanada S, Mita T, Nishino N, Tanaka C (1987) [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci 40:259–266
Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J, Davis KL (1998) Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 155:1080–1086
Heaton RK, Vogt AT, Hoehn MM, Lewis JA, Crowley TJ, Stallings MA (1979) Neuropsychological impairment with schizophrenia vs. acute and chronic cerebral lesions. J Clin Psychol 35:46–53
Heresco-Levy U, Javitt DC (1998) The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacol 8:141–152
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610–617
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1998) Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvent therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol 1:131–135
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M (1999) Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29–36
Hoffman RE, Cavus I (2002) Slow transcranial magnetic stimulation, long-term depotentiation, and brain hyperexcitability disorders. Am J Psychiatry 159:1093–1102
Hoffman RE, McGlashan TH (1997) N-methyl-D-aspartate receptor hypofunction in schizophrenia could arise from reduced cortical connectivity rather than receptor dysfunction [letter; comment]. Arch Gen Psychiatry 54:578–580
Hoffman RE, Buchsbaum MS, Escobar MD, Makuch RW, Nuechterlein KH, Guich SM (1991) EEG coherence of prefrontal areas in normal and schizophrenic males during perceptual activation. J Neuropsychiatry Clin Neurosci 3:169–175
Hoffman RE, Boutros NN, Berman RM, Krystal JH, Charney DS (2000) Transcranial magnetic stimulation of left temporoparietal cortex inpatients reporting auditory hallucinations. Lancet 355:1074–1076
Hoffman RE, Hawkins K, Gueorgueva R, Boutros NN, Rachid F, Carroll K, Krystal JH (2003) One hertz transcranial magnetic stimulation of temporoparietal cortex reduces medication-resistant auditory hallucinations. Arch Gen Psychiatry 60:49–56
Hyman SE, Fenton WS (2003) Medicine: what are the right targets for psychopharmacology? Science 299:350–351
Idvall J, Ahlgren I, Aronsen KR, Stenberg P (1979) Ketamine infusions: pharmacokinetics and clinical effects. Br J Anaesth 51:1167–1173
Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, Uzunov DP, Smalheiser NR, Davis JM, Pandey GN, Pappas GD, Tueting P, Sharma RP, Costa E (1998) A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 95:15718–15723
Ivanovic A, Reilander H, Laube B, Kuhse J (1998) Expression and initial characterization of a soluble glycine binding domain of the N-methyl-D-aspartate receptor NR1 subunit. J Biol Chem 273:19933–19937
Jackson PF, Cole DC, Slusher BS, Stetz SL, Ross LE, Donzanti BA, Trainor DA (1996) Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem 39:619–622
Javitt DC, Zukin SR (1989) Biexponential kinetics of [3H]MK-801 binding: evidence for access to closed and open N-methyl-D-aspartate receptor channels. Mol Pharmacol 35:387–393
Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234–1236
Javitt DC, Sershen H, Hashim A, Lajtha A (1997) Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 17:202–204
Jentsch JD, Elsworth JD, Redmond DE Jr, Roth RH (1997) Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966. J Neurosci 17:1769–1775
Johnson JW, Ascher P (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325:529–531
Kalus P, Senitz D, Beckmann H (1997) Altered distribution of parvalbumin-immunoreactive local circuit neurons in the anterior cingulate cortex of schizophrenic patients. Psychiatry Res 75:49–59
Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763–771
Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzepine in schizophrenia. Am J Psychiatry 156:286–293
Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Mann JJ, Laruelle M (1999) Ketamine modulation of amphetamine-induced striatal dopamine release in humans. Biol Psychiatry 45:20S
Kempermann G, Gage FH (1999) Experience-dependent regulation of adult hippocampal neurogenesis: effects of long-term stimulation and stimulus withdrawal. Hippocampus 9:321–332
Kempermann G, Kuhn HG, Gage FH (1998) Experience-induced neurogenesis in the senescent dentate gyrus. J Neurosci 18:3206–3212
Klein E, Bental E, Lerer B, Belmaker RH (1984) Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses: a controlled study. Arch Gen Psychiatry 41:165–170
Koenig T, Lehmann D, Saito N, Kuginuki T, Kinoshita T, Koukkou M (2001) Decreased functional connectivity of EEG theta-frequency activity in first-episode, neuroleptic-naive patients with schizophrenia: preliminary results. Schizophr Res 50:55–60
Kovelman JA, Scheibel AB (1984) A neurohistological correlate of schizophrenia. Biol Psychiatry 19:1601–1621
Kramer MS, Last B, Getson A, Reines SA (1997) The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group [published erratum appears in Arch Gen Psychiatry (1997 ) 54:1080]. Arch Gen Psychiatry 54:567–572
Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E et al. (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors [see comments]. Science 281:1640–1645
Krstulovic AM (1999) High-throughout screening in combinatorial chemistry for drug discovery. J Chromatogr B Biomed Sci Appl 725:1
Krupitsky EM, Burakov AM, Romanova TN, Grinenko NI, Grinenko AY, Fletcher J, Petrakis IL, Krystal JH (2001) Attenuation of ketamine effects by nimodipine in recently detoxified ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. Neuropsychopharmacology 25:936–947
Krystal J, D'Souza DC (1998) D-serine and the therapeutic challenge posed by the NMDA antagonist model of schizophrenia. Biol Psychiatry 44:1075–1076
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214
Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB Jr, Suckow RF, Stetson P, Heninger GR, Charney DS (1998a) Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology 135:213–229
Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS (1998b) Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry 55:354–360
Krystal JH, Abi-Dargham A, Laruelle M, Moghaddam B (1999a) Pharmacologic model psychoses. In: Charney DS, Nestler E, Bunney BS (eds) Neurobiology of Mental Illness. Oxford University Press, New York, pp 214–224
Krystal JH, Belger A, D'Souza DC, Anand A, Charney DS, Aghajanian GK, Moghaddam B (1999b) Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology 22: S143–S157
Krystal JH, D'Souza DC, Belger A, Cassello K, Madonick S, Sernyak M, Abi-Saab W (1999c) Amphetamine pretreatment reduces attention deficits, but not psychosis, produced by ketamine in healthy human subjects. Schizophr Res 36:309
Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Bowers MB Jr, Jatlow P, Heninger GR, Charney DS (1999d) Interactive effects of subanesthetic ketamine and haloperidol. Psychopharmacology 145:193–204
Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman R, Charney DS, Abi-Saab W, Madonick S (1999e) NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies for neuropsychiatric disorders. Harv Rev Psychiatry 7:125–133
Krystal JH, Belger A, Abi-Saab W, Moghaddam B, Charney DS, Anand A, Madonick S, D'Souza DC (2000) Glutamatergic contributions to cognitive dysfunction in schizophrenia. In: Harvey PD, Sharma T (eds) Cognitive Functioning in Schizophrenia. Oxford University Press, London
Krystal JH, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF (2002) Glutamate and GABA systems as targets for novel antidepressant and mood stabilizing treatments. Mol Psychiatry 7: S71–S80
Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, McDougall L, Belger A, Levine L, Breier A (2003a) Attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the the group II metabotropic glutamate receptor (mGluR) agonist, LY354740, in healthy human subjects. (in review)
Krystal JH, Petrakis IL, Mason G, D'Souza DC (2003b) NMDA glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmcol Ther (in press)
Kubicki M, Westin CF, Maier SE, Frumin M, Nestor PG, Salisbury DF, Kikinis R, Jolesz FA, McCarley RW, Shenton ME (2002) Uncinate fasciculus findings in schizophrenia: a magnetic resonance diffusion tensor imaging study. Am J Psychiatry 159:813–820
Kwon JS, O'Donnell BF, Wallenstein GV, Greene RW, Hirayasu Y, Nestor PG, Hasselmo ME, Potts GF, Shenton ME, McCarley RW (1999) Gamma frequency-range abnormalities to auditory stimulation in schizophrenia [comment]. Arch Gen Psychiatry 56:1001–1005
Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995a) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6:869–872
Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995b) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9–19
Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455–467
Lan JY, Skeberdis VA, Jover T, Zheng X, Bennett MV, Zukin RS (2001) Activation of metabotropic glutamate receptor 1 accelerates NMDA receptor trafficking. J Neurosci 21:6058–6068
Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235–9240
Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56–72
Lawrie SM, Buechel C, Whalley HC, Frith CD, Friston KJ, Johnstone EC (2002) Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry 51:1008–1011
Lee KH, Williams LM, Haig A, Goldberg E, Gordon E (2001) An integration of 40 Hz Gamma and phasic arousal: novelty and routinization processing in schizophrenia. Clin Neurophysiol 112:1499–1507
Lewis DA (2000) GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res Brain Res Rev 31:270–276
Lewis DA, Pierri JN, Volk DW, Melchitzky DS, Woo TU (1999) Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry 46:616–626
Lim KO, Sullivan EV, Zipursky RB, Pfefferbaum A (1996) Cortical gray matter volume deficits in schizophrenia: a replication. Schizophr Res 20:157–164
Lim KO, Hedehus M, Moseley M, de Crespigny A, Sullivan EV, Pfefferbaum A (1999) Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. Arch Gen Psychiatry 56:367–374
Lisman JE, Fellous J-M, Wang X-J (1998) A role for NMDA-receptor channels in working memory. Nature Neurosci 1:273–276
Loebel AD, Kane JM, Chipkin Re, Casey D, Czernansky J, Krystal JH, Marder S, McEvoy J, Rotrosen J (1999) The efficacy and safety of SCH39166, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia: an open clinical trial. (in review)
Longson D, Deakin JF, Benes FM (1996) Increased density of entorhinal glutamate-immunoreactive vertical fibers in schizophrenia. J Neural Transm (Budapest) 103:503–507
Lopez-Corcuera B, Geerlings A, Aragon C (2001) Glycine neurotransmitter transporters: an update. Mol Membr Biology 18:13–20
Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug—sernyl. Arch Neurol Psychiatry 81:363–369
Lujan R, Roberts JD, Shigemoto R, Ohishi H, Somogyi P (1997) Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites. J Chem Neuroanat 13:219–241
Lysaker PH, Bell MD, Bioty S, Zito WS (1996) Performance on the Wisconsin Card Sorting Test as a predictor of rehospitalization in schizophrenia. J Nerv Ment Dis 184:319–321
Maccaferri G, Dingledine R (2002) Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons. J Neurosci 22:5462–5472
Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141–150
Mann K, Maier W, Franke P, Roschke J, Gansicke M (1997) Intra- and interhemispheric electroencephalogram coherence in siblings discordant for schizophrenia and healthy volunteers. Biol Psychiatry 42:655–663
Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825–835
Marenco S, Egan MF, Goldberg TE, Knable MB, McClure RK, Winterer G, Weinberger DR (2002) Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res 57:221–226
Martin P, Carlsson ML, Hjorth S (1998) Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport 9:2985–2988
Mathalon DH, Ford JM, Pfefferbaum A (2000) Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol Psychiatry 47:434–449
Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A (2001) Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 58:148–157
McCarley RW, Salisbury DF, Hirayasu Y, Yurgelun-Todd DA, Tohen M, Zarate C, Kikinis R, Jolesz FA, Shenton ME (2002) Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in first-episode schizophrenia. Arch Gen Psychiatry 59:321–331
McCoy L, Richfield EK (1996) Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci Lett 213:137–141
McGlashan TH, Fenton WS (1993) Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull 19:71–84
Meador-Woodruff JH, Healy DJ (2000) Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 31:288–294
Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238–246
Mercadante S (1996) Ketamine in cancer pain: an update. Palliat Med 10:225–230
Meyer-Lindenberg A, Poline JB, Kohn PD, Holt JL, Egan MF, Weinberger DR, Berman KF (2001) Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am J Psychiatry 158:1809–1817
Michelogiannis S, Paritsis N, Trikas P (1991) EEG coherence during hemispheric activation in schizophrenics. Eur Arch Psychiatry Clin Neurosci 241:31–34
Mizukami K, Sasaki M, Ishikawa M, Iwakiri M, Hidaka S, Shiraishi H, Iritani S (2000) Immunohistochemical localization of gamma-aminobutyric acid(B) receptor in the hippocampus of subjects with schizophrenia. Neurosci Lett 283:101–104
Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349–1352
Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921–2927
Nachshoni T, Levin Y, Levy A, Kritz A, Neumann M (1994) A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatry 35:22–26
Nagarajan N, Quast C, Boxall AR, Shahid M, Rosenmund C (2001) Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546. Neuropharmacology 41:650–663
Newcomer JW, Krystal JH (2001) NMDA regulation of memory function and behavior in humans. Hippocampus 11:529–542
Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Kelly Melson A, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as model of memory impairment and psychosis. Neuropsychopharmacology 20:106–118
Nicoll RA, Malenka RC (1999) Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann NY Acad Sci 868:515–525
Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC (1999) Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABA(A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression. Neuroscience 93:441–448
Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K (1989) A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 80:250–259
Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998–1007
Ongur D, Drevets WC, Price JL (1998) Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 95:13290–13295
Oye I, Paulsen O, Maurset A (1992) Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 260:1209–1213
Pallotta M, Segieth J, Whitton PS (1998) N-methyl-d-aspartate receptors regulate 5-HT release in the raphe nuclei and frontal cortex of freely moving rats: differential role of 5-HT1A autoreceptors. Brain Res 783:173–178
Penfield W, Perot P (1963) The brain's record of auditory and visual experience. Brain 86:595–696
Pierri JN, Chaudry AS, Woo TU, Lewis DA (1999) Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry 156:1709–1719
Post RM (1999) Comparative pharmacology of bipolar disorder and schizophrenia. Schizophr Res 39:153–158, 163
Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B (1999) Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 156:145–147
Price WA (1987) Antipsychotic effects of verapamil in schizophrenia. Hillside J Clin Psychiatry 9:225–230
Priestley T, Kemp JA (1994) Kinetic study of the interactions between the glutamate and glycine recognition sites on the N-methyl-D-aspartic acid receptor complex. Mol Pharmacol 46:1191–1196
Quinlan EM, Philpot BD, Huganir RL, Bear MF (1999) Rapid, experience-dependent expression of synaptic NMDA receptors in visual cortex in vivo. Nature Neurosci 2:352–357
Radant AD, Bowdle TA, Cowley DS, Kharasch ED, Roy-Byrne PP (1998) Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 19:434–444
Rajkowska G, Selemon LD, Goldman-Rakic PS (1998) Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 55:215–224
Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA (1999) Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45:1085–1098
Rao SG, Williams GV, Goldman-Rakic PS (1999) Isodirectional tuning of adjacent interneurons and pyramidal cells during working memory: evidence for microcolumnar organization in PFC. J Neurophysiol 81:1903–1916
Rao SG, Williams GV, Goldman-Rakic PS (2000) Destruction and creation of spatial tuning by disinhibition: GABA-A blockade of prefrontal cortical neurons engaged by working memory. J Neurosci 20:485–494
Reich DL, Silvay G (1989) Ketamine: an update on the first twenty-five years of clinical experience. Can J Aneasth 36:186–197
Reiter S, Adler L, Angrist B, Peselow E, Rotrosen J (1989) Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. J Clin Psychiatry 50:26–27
Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D (1997) A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 337:809–815
Rosoklija G, Toomayan G, Ellis SP, Keilp J, Mann JJ, Latov N, Hays AP, Dwork AJ (2000) Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch Gen Psychiatry 57:349–356
Saba G, Dumortier G, Kalalou K, Benadhira R, Degrassat K, Glikman J, Januel D (2002) Lamotrigine--clozapine combination in refractory schizophrenia: three cases. J Neuropsychiatry Clin Neurosci 14:86
Sarhan S, Hitchcock JM, Grauffel CA, Wettstein JG (1997) Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Peptides 18:1223–1227
Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC (1994) Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 51:124–131
Schell MJ, Molliver ME, Snyder SH (1995) D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci USA 92:3948–3952
Schell MJ, Brady RO Jr, Molliver ME, Snyder SH (1997) D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors. J Neurosci 17:1604–1615
Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299:12–20
Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC (2001) Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50:521–530
Selemon LD, Goldman-Rakic PS (1999) The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 45:17–25
Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S (2001) Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 24:330–334
Shen M, Thayer SA (1999) Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Mol Pharmacol 55:8–13
Shergill SS, Brammer MJ, Williams SC, Murray RM, McGuire PK (2000) Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry 57:1033–1038
Siegel BV Jr, Buchsbaum MS, Bunney WE Jr, Gottschalk LA, Haier RJ, Lohr JB, Lottenberg S, Najafi A, Nuechterlein KH, Potkin SG et al (1993) Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry 150:1325–1336
Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, McKenna P, Chua SE, Schnorr L et al (1995) A functional neuroanatomy of hallucinations in schizophrenia. Nature 378:176–179
Simosky JK, Stevens KE, Freedman R (2002) Nicotinic agonists and psychosis. Curr Drug Targets Cns Neurolog Disord 1:149–162
Simpson MD, Slater P, Deakin JF, Royston MC, Skan WJ (1989) Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 107:211–215
Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH (2001) Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry 158:1393–1399
Snyder GL, Fienberg AA, Huganir RL, Greengard P (1998) A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J Neurosci 18:10297–10303
Speer AM, Kimbrell TA, Wassermann EM, J DR, Willis MW, Herscovitch P, Post RM (2000) Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. Biol Psychiatry 48:1133–1141
Spencer RW (1998) High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. Biotechnol Bioeng 61:61–67
Stedman TJ, Whiteford HA, Eyles D, Welham JL, Pond SM (1991) Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients. J Clin Psychopharmacol 11:43–47
Steel RM, Bastin ME, McConnell S, Marshall I, Cunningham-Owens DG, Lawrie SM, Johnstone EC, Best JJ (2001) Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls. Psychiatry Res 106:161–170
Stefani A, Spadoni F, Siniscalchi A, Bernardi G (1996) Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol 307:113–116
Stefani A, Spadoni F, Bernardi G (1997) Voltage-activated calcium channels: targets of antiepileptic drug therapy? Epilepsia 38:959–965
Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT et al. (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71:877–892
Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY (1993) Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266:1374–1384
Suddath RL, Straw GM, Freed WJ, Bigelow LB, Kirch DG, Wyatt RJ (1991) A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Pharmacol Biochem Behav 39:743–75
Suppiramaniam V, Bahr BA, Sinnarajah S, Owens K, Rogers G, Yilma S, Vodyanoy V (2001) Member of the Ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptors. Synapse 40:154–158
Supplisson S, Bergman C (1997) Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci 17:4580–4590
Takahata R, Moghaddam B (1998) Glutamatergic regulation of basal and stimulus-activated dopamine release in the prefrontal cortex. J Neurochem 71:1443–1449
Tamminga CA (1998) Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12:21–36
Tang YP, Wang H, Feng R, Kyin M, Tsien JZ (2001) Differential effects of enrichment on learning and memory function in NR2B transgenic mice. Neuropharmacology 41:779–790
Tauscher J, Fischer P, Neumeister A, Rappelsberger P, Kasper S (1998) Low frontal electroencephalographic coherence in neuroleptic-free schizophrenic patients. Biol Psychiatry 44:438–447
Thompson PM, Vidal C, Giedd JN, Gochman P, Blumenthal J, Nicolson R, Toga AW, Rapoport JL (2001) Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci USA 98:11650–11655
Tiihonen J, Hallikainen T, Ryynänen O-P, Repo-Tiihonen E, Kotilainen I, Eronen M, Toivonen P, Wahlbeck K, Putkonen A (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54:1–6
Todtenkopf MS, Benes FM (1998) Distribution of glutamate decarboxylase65 immunoreactive puncta on pyramidal and nonpyramidal neurons in hippocampus of schizophrenic brain. Synapse 29:323–332
Tollefson GD, Sanger TM (1997) Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154:466–474
Toth E, Lajtha A (1986) Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res 11:393–400
Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Riviere M-E, Papillon-Downy C, Group FS (1999) A placebo controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry 156:419–425
Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, Coyle JT (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 52:829–836
Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081–1089
Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT (1999) D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 156:1822–1825
Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, Doan A, Aakalu VK, Lanahan AA, Sheng M, Worley PF (1999) Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23:583–592
Ugolini A, Corsi M, Bordi F (1999) Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons. Neuropharmacology 38:1569–1576
Umbricht D, Vollenweider FX (1999) Effects of NMDA-antagonists and 5-HT2A-agonists on generation of MMN in human volunteers. Biol Psychiatry 45:51S–52S
Van Hijfte L, Marciniak G, Froloff N (1999) Combinatorial chemistry, automation and molecular diversity: new trends in the pharmaceutical industry. J Chromatogr B Biomed Sci Appl 725:3–15
Verhoeff NPLG, Soares JC, D'Souza DC, Gil R, Degen K, Abi-Dargham A, Zoghbi SS, Fujita M, Rajeevan N, Seibyl JP, Krystal JH, van Dyck CH, Charney DS, Innis RB (1999) [123I]iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res Neuroimaging 91:163–173
Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA (2000) Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 57: 237–245
Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, Lewis DA (2002) Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 12:1063–1070
Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56:495–507
Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7:25–38
Wada Y, Nanbu Y, Jiang ZY, Koshino Y, Hashimoto T (1998) Interhemispheric EEG coherence in never-medicated patients with paranoid schizophrenia: analysis at rest and during photic stimulation. Clin Electroencephalogr 29:170–176
Waldmeier PC, Martin P, Stocklin K, Portet C, Schmutz M (1996) Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum. Naunyn Schmiedebergs Arch Pharmacol 354:164–172
Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW (1996) Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 7:3037–3040
Wang XJ (1999) Synaptic basis of cortical persistent activity: the importance of NMDA receptors to working memory. J Neurosci 19:9587–9603
Weinberger DR, Berman KF, Zec RF (1986) Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence.[comment]. Arch Gen Psychiatry 43:114–124
Weinberger DR, Berman KF, Suddath R, Torrey EF (1992) Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 149:890–897
Werner P, Pitt D, Raine CS (2001) Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50:169–180
Wexler BE, Anderson M, Fulbright RK, Gore JC (2000) Preliminary evidence of improved verbal working memory performance and normalization of task-related frontal lobe activation in schizophrenia following cognitive exercises [comment]. Am J Psychiatry 157:1694–1697
Wible CG, Shenton ME, Hokama H, Kikinis R, Jolesz FA, Metcalf D, McCarley RW (1995) Prefrontal cortex and schizophrenia. A quantitative magnetic resonance imaging study. Arch Gen Psychiatry 52:279–288
Wieber J, Gugler R, Hengstmann JH, Dengler HJ (1975) Pharmacokinetics of ketamine in man. Anaesthesist 24:260–263
Wiesel FA, Nordstrom AL, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114:31–38
Williamson PC, Bartha R, Drost D, Menon R, Malla A, Carr T, Neufeld RWJ (1999) Glutamate and glutamine on 1H MRS in never-treated schizophrenic patients. Schizophr Res 36:249
Wilson WH, Ban TA, Guy W (1985) Pharmacotherapy of chronic hospitalized schizophrenics: prescription practices. Neuropsychobiology 14:75–82
Winterer G, Egan MF, Radler T, Hyde T, Coppola R, Weinberger DR (2001) An association between reduced interhemispheric EEG coherence in the temporal lobe and genetic risk for schizophrenia. Schizophr Res 49:129–143
Woo TU, Miller JL, Lewis DA (1997) Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Am J Psychiatry 154:1013–1015
Yamada K, Kanba S, Ashikari I, Ohnishi K, Yagi G, Asai M (1996) Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. J Clin Psychopharmacol 16:437–439
Yonezawa Y, Kuroki T, Kawahara T, Tashiro N, Uchimura H (1998) Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur J Pharmacol 341:45–56
Young D, Lawlor PA, Leone P, Dragunow M, During MJ (1999) Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nat Med 5:448–453
Yuste R, Majewska A, Cash SS, Denk W (1999) Mechanisms of calcium influx into hippocampal spines: heterogeneity among spines, coincidence detection by NMDA receptors, and optical quantal analysis. J Neurosci 19:1976–1987
Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 154:782–791
Acknowledgements
The authors acknowledge the support from the Department of Veterans Affairs via the Schizophrenia Biological Research Center, Alcohol Research Center, VA National Center for PTSD, Career Development Program (D.M.), Cooperative Studies Career Development Program (E.P.), and Merit Review Program (J.K.). The work outlined in this review has also been supported by the National Institute of Mental Health (5P50 MH44866-12), National Institute on Alcohol Abuse and Alcoholism (KO2 AA 00261-01), and the National Alliance for Research on Schizophrenia and Affective Disorders. The authors gratefully acknowledge the helpful input of colleagues with whom we have discussed topics related to this review including Bita Moghaddam, Ph.D., Judith Ford, Ph.D., John Lisman, Ph.D., and Robert Greene, M.D., Ph.D.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Krystal, J.H., D'Souza, D.C., Mathalon, D. et al. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169, 215–233 (2003). https://doi.org/10.1007/s00213-003-1582-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1582-z